A press release from the FDA (Food and Drug Administration). The U.S. Food and Drug Administration has approved the pediatric use of Protopam Chloride (pralidoxime chloride), a drug used to treat poisoning by organophosphate pesticides and chemicals (e.g., nerve agents). The drug is approved to be administered either by intravenous (IV) or intramuscular (IM) injections. [1] I did a quick search for pediatric versions of the pralidoxime autoinjector. I did not find anything. That does not mean that they do not exist. I tried to contact the FDA and AAP (American Academy of Pediatrics) about this. The press release was at 16:24 during a holiday week. It is not surprising that I got voice mail at the FDA (at about 17:05) and an out of office email auto reply from the AAP later on. This is not a press release that appears to be well thought out. While there is a lot of useful information in there, there is not any mention of pediatric versions of the pralidoxime autoinjectors. There is not any mention of pediatric dosage of pralidoxime. This is something that the AAP has been pushing for since 2008, so an extra day to address these, and other, issues is not unreasonable. I would say that we should wait until after the weekend, so that there is a full work week to address this, but with the fear of attack that goes with 9/11, this probably satisfies those who do not seem to get enough Ativan in their diets. Oh, joy. What else does the press release say? Protopam Chloride was approved by the FDA in 1964 to treat various types of pesticide and chemical poisoning in adults. The drug works as an antidote to pesticides and chemicals of the organophosphate class by slowing the attachment of the chemical to nerve endings.

Original Source of FDA approves pediatric use of pralidoxime chloride for organophosphate poisoning